Privium Fund Management B.V. Sells 646,755 Shares of ProQR Therapeutics (NASDAQ:PRQR)

Privium Fund Management B.V. cut its holdings in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 11.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,985,633 shares of the biopharmaceutical company's stock after selling 646,755 shares during the period. ProQR Therapeutics accounts for approximately 3.0% of Privium Fund Management B.V.'s investment portfolio, making the stock its 7th biggest holding. Privium Fund Management B.V. owned about 6.10% of ProQR Therapeutics worth $13,212,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PRQR. BNP Paribas Financial Markets boosted its stake in ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC lifted its stake in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after buying an additional 15,550 shares during the period. Ballentine Partners LLC purchased a new stake in shares of ProQR Therapeutics during the fourth quarter valued at $61,000. PNC Financial Services Group Inc. purchased a new stake in ProQR Therapeutics during the 4th quarter valued at about $77,000. Finally, Raymond James Financial Inc. acquired a new position in shares of ProQR Therapeutics in the fourth quarter valued at about $260,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

Remove Ads

ProQR Therapeutics Price Performance

PRQR stock traded up $0.02 during midday trading on Friday, hitting $1.65. 629,073 shares of the stock traded hands, compared to its average volume of 550,770. The stock's fifty day simple moving average is $2.16 and its 200-day simple moving average is $2.61. The firm has a market cap of $134.77 million, a P/E ratio of -5.16 and a beta of 0.24. ProQR Therapeutics has a 1-year low of $1.59 and a 1-year high of $4.62.

Wall Street Analyst Weigh In

A number of research firms recently commented on PRQR. Citigroup raised ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price for the company in a report on Monday, March 10th. HC Wainwright lifted their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, March 14th. JMP Securities reiterated a "market outperform" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Friday, March 14th. Finally, Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $9.50.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).